SCHEMBL5579088

SCHEMBL5579088

CC(C)(C)OC(=O)N1CCC2(CC1)CNc1cc(C(F)(F)F)ccc12

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 1/20 0.46
MAPT P10636 1/20 0.45
GPR119 Q8TDV5 5/20 0.42
SYK P43405 2/20 0.41
STS P08842 1/20 0.40
HDAC1 Q13547 2/20 0.39
HDAC8 Q9BY41 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
PDK2 Q15119 1/20 0.39
MAPK1 P28482 1/20 0.38
USP30 Q70CQ3 1/20 0.38
ENPP2 Q13822 1/20 0.38
RORC P51449 2/20 0.38
JAK2 O60674 2/20 0.38
JAK1 P23458 1/20 0.38
JAK3 P52333 1/20 0.38
PTK2 Q05397 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5578656 0.87 TNKS (0.44) TACR1GPR119HDAC1HDAC8HDAC6
SCHEMBL16162422 0.85 USP30 (0.43) TACR1MAPTGPR119SYKSTS
SCHEMBL16162442 0.85 USP30 (0.43) TACR1MAPTGPR119SYKSTS
SCHEMBL16086562 0.85 USP30 (0.43) TACR1MAPTGPR119SYKSTS
SCHEMBL1195130 0.84 AVPR1A (0.47) STSHDAC1HDAC8HDAC6MAPK1
SCHEMBL1195132 0.84 AVPR1A (0.47) STSHDAC1HDAC8HDAC6MAPK1
SCHEMBL5578756 0.84 ALDH1A1 (0.46) MAPTGPR119STSHDAC1HDAC8
SCHEMBL12877996 0.82 MAPK1 (0.38) TACR1MAPTGPR119HDAC1HDAC8
SCHEMBL1195962 0.82 GPR119 (0.44) GPR119MAPK1USP30JAK2JAK1
SCHEMBL1195964 0.82 GPR119 (0.44) GPR119MAPK1USP30JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3087072-A2 SPIROINDOLINE ANTIPARASITIC DERIVATIVES Zoetis Services LLC (US) 2016-11-02 EP disclosed
US-20160296499-A1 Spiroindoline Antiparasitic Derivatives ZOETIS SERVICES LLC 2016-10-13 US disclosed
WO-2015100232-A2 SPIROINDOLINE ANTIPARASITIC DERIVATIVES ZOETIS SERVICES LLC (US) 2015-07-02 WO disclosed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
EP-1716148-A2 NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF Arena Pharmaceuticals, Inc. (US) 2006-11-02 EP disclosed
WO-2005063745-A2 NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF ARENA PHARMACEUTICALS, INC. (US) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof REN, AVPR2, RECQL TACR1 224/4885MAPT 2939/4885GPR119 517/4885
US-20160296499-A1 Spiroindoline Antiparasitic Derivatives PKD2, PKD1, AVPR2 TACR1 26/4885MAPT 4482/4885GPR119 2154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.